Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 41 | 2025 | 264 | 8.320 |
Why?
| | Chemical and Drug Induced Liver Injury | 16 | 2023 | 139 | 4.650 |
Why?
| | Analgesics, Non-Narcotic | 22 | 2025 | 123 | 4.550 |
Why?
| | Drug Overdose | 32 | 2025 | 367 | 3.990 |
Why?
| | Poison Control Centers | 13 | 2025 | 84 | 3.400 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2301 | 3.090 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.850 |
Why?
| | Acetylcysteine | 12 | 2023 | 138 | 2.530 |
Why?
| | Alanine Transaminase | 14 | 2023 | 151 | 2.490 |
Why?
| | Cocaine | 10 | 2011 | 160 | 2.330 |
Why?
| | Cannabis | 9 | 2020 | 509 | 2.230 |
Why?
| | Prescription Drugs | 9 | 2018 | 110 | 2.130 |
Why?
| | Antidotes | 10 | 2023 | 145 | 1.610 |
Why?
| | Legislation, Drug | 5 | 2017 | 73 | 1.420 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1131 | 1.410 |
Why?
| | Cysteine | 4 | 2017 | 210 | 1.290 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 207 | 1.270 |
Why?
| | Marijuana Use | 4 | 2021 | 213 | 1.140 |
Why?
| | Medication Errors | 5 | 2015 | 83 | 1.110 |
Why?
| | Pain | 9 | 2020 | 777 | 1.050 |
Why?
| | Emergency Medicine | 6 | 2019 | 261 | 1.040 |
Why?
| | Male | 103 | 2022 | 72035 | 1.030 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 130 | 1.030 |
Why?
| | Humans | 156 | 2025 | 144261 | 1.020 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.010 |
Why?
| | Toxicology | 4 | 2021 | 49 | 1.000 |
Why?
| | Medication Reconciliation | 2 | 2016 | 31 | 0.920 |
Why?
| | Female | 96 | 2023 | 77976 | 0.900 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2026 | 0.900 |
Why?
| | Adult | 73 | 2022 | 40262 | 0.890 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 31 | 0.850 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.850 |
Why?
| | Antivenins | 5 | 2019 | 29 | 0.850 |
Why?
| | Diphenhydramine | 4 | 2023 | 36 | 0.830 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 5 | 0.820 |
Why?
| | Thiazoles | 4 | 2009 | 135 | 0.800 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 17 | 0.790 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.790 |
Why?
| | Benzodiazepines | 6 | 2023 | 165 | 0.780 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.760 |
Why?
| | Lorazepam | 3 | 2023 | 25 | 0.750 |
Why?
| | Heart Arrest | 8 | 2018 | 407 | 0.740 |
Why?
| | Young Adult | 30 | 2020 | 13990 | 0.720 |
Why?
| | Middle Aged | 54 | 2022 | 35762 | 0.710 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.700 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 338 | 0.700 |
Why?
| | Emergency Treatment | 4 | 2015 | 124 | 0.700 |
Why?
| | Seizures | 6 | 2011 | 460 | 0.690 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.690 |
Why?
| | Medical History Taking | 3 | 2018 | 115 | 0.690 |
Why?
| | Piperazines | 4 | 2009 | 380 | 0.690 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 58 | 0.690 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 265 | 0.680 |
Why?
| | Referral and Consultation | 2 | 2020 | 847 | 0.680 |
Why?
| | Delirium | 2 | 2020 | 104 | 0.670 |
Why?
| | Abdominal Pain | 2 | 2019 | 146 | 0.650 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 141 | 0.630 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.620 |
Why?
| | Suicide, Attempted | 5 | 2012 | 404 | 0.620 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 144 | 0.620 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 555 | 0.620 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 81 | 0.610 |
Why?
| | Buprenorphine | 2 | 2020 | 181 | 0.600 |
Why?
| | Patient Handoff | 1 | 2020 | 42 | 0.590 |
Why?
| | Haloperidol | 1 | 2019 | 33 | 0.590 |
Why?
| | Ketorolac | 1 | 2019 | 30 | 0.580 |
Why?
| | Retrospective Studies | 31 | 2023 | 17009 | 0.580 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.580 |
Why?
| | Emergency Medical Services | 5 | 2025 | 696 | 0.570 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 22 | 0.570 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.560 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 56 | 0.550 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 187 | 0.550 |
Why?
| | Vomiting | 6 | 2019 | 130 | 0.550 |
Why?
| | Colorado | 15 | 2021 | 4562 | 0.550 |
Why?
| | Hypotension | 2 | 2022 | 126 | 0.540 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1054 | 0.530 |
Why?
| | Prospective Studies | 18 | 2023 | 7970 | 0.530 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.530 |
Why?
| | Child | 28 | 2023 | 22537 | 0.520 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.510 |
Why?
| | Medical Marijuana | 2 | 2019 | 123 | 0.510 |
Why?
| | Cannabinoids | 3 | 2017 | 182 | 0.500 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 93 | 0.500 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.500 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 243 | 0.500 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.500 |
Why?
| | Electronic Health Records | 4 | 2024 | 1169 | 0.490 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 52 | 0.490 |
Why?
| | Hypocalcemia | 1 | 2016 | 38 | 0.480 |
Why?
| | Health Records, Personal | 1 | 2016 | 26 | 0.480 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 65 | 0.470 |
Why?
| | Blood Proteins | 1 | 2017 | 249 | 0.460 |
Why?
| | Mobile Applications | 1 | 2018 | 196 | 0.460 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 257 | 0.460 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.460 |
Why?
| | Antidepressive Agents | 2 | 2012 | 242 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1347 | 0.450 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 50 | 0.440 |
Why?
| | Liver | 6 | 2022 | 1884 | 0.440 |
Why?
| | Electrocardiography | 5 | 2013 | 660 | 0.430 |
Why?
| | Infant | 13 | 2023 | 10022 | 0.430 |
Why?
| | Treatment Outcome | 18 | 2020 | 11643 | 0.420 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 97 | 0.410 |
Why?
| | Child, Preschool | 13 | 2018 | 11774 | 0.410 |
Why?
| | Crime | 2 | 2011 | 60 | 0.410 |
Why?
| | Observer Variation | 3 | 2010 | 354 | 0.400 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.400 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.400 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 11 | 0.390 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.390 |
Why?
| | Plasmapheresis | 1 | 2013 | 22 | 0.390 |
Why?
| | Diet Surveys | 1 | 2013 | 91 | 0.390 |
Why?
| | Accidents | 1 | 2013 | 45 | 0.390 |
Why?
| | Bradycardia | 1 | 2013 | 59 | 0.390 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 360 | 0.390 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.380 |
Why?
| | Adolescent | 27 | 2020 | 22281 | 0.380 |
Why?
| | Hematemesis | 1 | 2012 | 4 | 0.380 |
Why?
| | Phytotherapy | 1 | 2013 | 74 | 0.380 |
Why?
| | Double-Blind Method | 7 | 2020 | 2025 | 0.380 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 85 | 0.380 |
Why?
| | Foreign Bodies | 2 | 2011 | 107 | 0.380 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.380 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.380 |
Why?
| | beta-Alanine | 1 | 2012 | 23 | 0.380 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 50 | 0.370 |
Why?
| | Citalopram | 1 | 2012 | 32 | 0.370 |
Why?
| | Liver Function Tests | 7 | 2020 | 106 | 0.370 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 778 | 0.360 |
Why?
| | Antithrombins | 1 | 2012 | 70 | 0.360 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.360 |
Why?
| | Antifungal Agents | 1 | 2013 | 149 | 0.360 |
Why?
| | Thiophenes | 1 | 2012 | 128 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2359 | 0.350 |
Why?
| | Anaphylaxis | 2 | 2012 | 102 | 0.350 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.350 |
Why?
| | C-Peptide | 2 | 2010 | 186 | 0.350 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 9 | 0.350 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.350 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 423 | 0.350 |
Why?
| | Dronabinol | 4 | 2021 | 247 | 0.340 |
Why?
| | Alcohol Drinking | 4 | 2012 | 812 | 0.340 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4556 | 0.340 |
Why?
| | Benzimidazoles | 1 | 2012 | 190 | 0.340 |
Why?
| | Temperance | 2 | 2010 | 20 | 0.340 |
Why?
| | Aged | 27 | 2019 | 25850 | 0.340 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.340 |
Why?
| | Administration, Intravenous | 4 | 2016 | 170 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 729 | 0.340 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 576 | 0.340 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 23 | 0.340 |
Why?
| | Brain Edema | 1 | 2011 | 62 | 0.330 |
Why?
| | Amitriptyline | 2 | 2001 | 24 | 0.330 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 108 | 0.330 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 136 | 0.320 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3403 | 0.320 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 181 | 0.320 |
Why?
| | Immunologic Factors | 2 | 2019 | 255 | 0.320 |
Why?
| | Liver Failure | 1 | 2011 | 83 | 0.320 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.320 |
Why?
| | Aged, 80 and over | 15 | 2018 | 8243 | 0.320 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.320 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.320 |
Why?
| | Burns | 2 | 2015 | 376 | 0.310 |
Why?
| | Population Surveillance | 1 | 2013 | 483 | 0.310 |
Why?
| | Barium | 1 | 2009 | 27 | 0.310 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.310 |
Why?
| | Time Factors | 12 | 2020 | 7155 | 0.310 |
Why?
| | Imines | 2 | 2022 | 6 | 0.310 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.310 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 45 | 0.300 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 97 | 0.300 |
Why?
| | United States | 18 | 2025 | 15876 | 0.300 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.300 |
Why?
| | Warfarin | 1 | 2010 | 170 | 0.300 |
Why?
| | Deception | 1 | 2009 | 18 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 67 | 0.300 |
Why?
| | Random Allocation | 3 | 2007 | 363 | 0.300 |
Why?
| | Benzoquinones | 2 | 2022 | 47 | 0.300 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 75 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5813 | 0.290 |
Why?
| | Odds Ratio | 7 | 2017 | 1072 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6021 | 0.290 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.290 |
Why?
| | Risk Assessment | 8 | 2017 | 3637 | 0.290 |
Why?
| | Risk Factors | 9 | 2017 | 10699 | 0.280 |
Why?
| | Oximetry | 1 | 2009 | 126 | 0.280 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 96 | 0.280 |
Why?
| | Length of Stay | 3 | 2020 | 1335 | 0.280 |
Why?
| | Cyanoacrylates | 1 | 2008 | 3 | 0.270 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.270 |
Why?
| | Adhesives | 1 | 2008 | 15 | 0.270 |
Why?
| | Reference Values | 4 | 2017 | 797 | 0.270 |
Why?
| | Detergents | 1 | 2008 | 44 | 0.270 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 187 | 0.270 |
Why?
| | Intellectual Disability | 1 | 2009 | 174 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 114 | 0.270 |
Why?
| | Hypoglycemia | 2 | 2010 | 477 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.270 |
Why?
| | Alcoholism | 4 | 2023 | 808 | 0.260 |
Why?
| | Animals | 22 | 2019 | 38030 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 649 | 0.260 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.260 |
Why?
| | Niacin | 1 | 2007 | 16 | 0.260 |
Why?
| | Diazepam | 1 | 2007 | 33 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 96 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 397 | 0.250 |
Why?
| | Vitamin B Complex | 1 | 2007 | 40 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.250 |
Why?
| | Thromboembolism | 1 | 2007 | 125 | 0.250 |
Why?
| | Pediatrics | 1 | 2015 | 1112 | 0.240 |
Why?
| | Specimen Handling | 1 | 2008 | 185 | 0.240 |
Why?
| | Pyrazoles | 2 | 2023 | 509 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 228 | 0.240 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.240 |
Why?
| | Decontamination | 1 | 2006 | 32 | 0.230 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 46 | 0.230 |
Why?
| | Amiodarone | 1 | 2005 | 31 | 0.230 |
Why?
| | Self Report | 4 | 2021 | 863 | 0.230 |
Why?
| | Age Factors | 7 | 2017 | 3313 | 0.230 |
Why?
| | Intention | 1 | 2007 | 183 | 0.230 |
Why?
| | Eating | 4 | 2017 | 389 | 0.230 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 19 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2007 | 194 | 0.230 |
Why?
| | Anticoagulants | 1 | 2010 | 721 | 0.230 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 375 | 0.220 |
Why?
| | Drug Utilization | 5 | 2014 | 166 | 0.220 |
Why?
| | Calcium | 3 | 2016 | 1182 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1705 | 0.220 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 70 | 0.220 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 338 | 0.220 |
Why?
| | Education, Medical | 2 | 2021 | 273 | 0.220 |
Why?
| | Coma | 2 | 2006 | 37 | 0.220 |
Why?
| | Databases, Factual | 1 | 2010 | 1484 | 0.210 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 862 | 0.210 |
Why?
| | Biomarkers | 7 | 2021 | 4254 | 0.210 |
Why?
| | Hospitals, Urban | 5 | 2021 | 144 | 0.200 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 116 | 0.200 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 45 | 0.200 |
Why?
| | Triage | 2 | 2025 | 249 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 8 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3592 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 11 | 0.190 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1983 | 0.190 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 213 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1379 | 0.190 |
Why?
| | Insulin | 3 | 2019 | 2501 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 119 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 291 | 0.190 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 192 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 91 | 0.180 |
Why?
| | Documentation | 1 | 2024 | 197 | 0.180 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 173 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2104 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 112 | 0.180 |
Why?
| | Confidence Intervals | 4 | 2010 | 333 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 340 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 186 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1129 | 0.170 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2917 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 23 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 121 | 0.170 |
Why?
| | Fractures, Bone | 2 | 2017 | 414 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 144 | 0.160 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 204 | 0.160 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 174 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 1028 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2001 | 298 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.150 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 3 | 0.150 |
Why?
| | Wisconsin | 1 | 2020 | 99 | 0.150 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.150 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.150 |
Why?
| | Starch | 1 | 2019 | 22 | 0.150 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.150 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 38 | 0.150 |
Why?
| | Survival Analysis | 4 | 2010 | 1382 | 0.150 |
Why?
| | Healthy Volunteers | 2 | 2019 | 214 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 205 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 37 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 179 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 24 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 231 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 847 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 6 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.140 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 150 | 0.140 |
Why?
| | Community Health Workers | 1 | 2020 | 85 | 0.140 |
Why?
| | Metabolome | 1 | 2022 | 384 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 187 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1044 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 527 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1332 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5935 | 0.140 |
Why?
| | Cannabidiol | 1 | 2020 | 136 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2096 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 22 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 234 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 9 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 397 | 0.130 |
Why?
| | Dyspnea | 1 | 1999 | 251 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2021 | 301 | 0.130 |
Why?
| | Dietary Fats | 1 | 2019 | 313 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1406 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 240 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 698 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 66 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 287 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 124 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2870 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 2088 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 4 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 355 | 0.120 |
Why?
| | Mice | 8 | 2009 | 18329 | 0.120 |
Why?
| | Energy Intake | 1 | 2019 | 499 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 306 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 134 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 114 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 64 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 151 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 214 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1050 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 405 | 0.120 |
Why?
| | Milk | 1 | 2016 | 119 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2111 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 982 | 0.110 |
Why?
| | Herniorrhaphy | 1 | 2016 | 74 | 0.110 |
Why?
| | Fatal Outcome | 2 | 2013 | 307 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 235 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1867 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 56 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1820 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 17 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 32 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 41 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 97 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 22 | 0.100 |
Why?
| | Oxycodone | 1 | 2014 | 53 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 938 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Food | 1 | 2015 | 149 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 178 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1057 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 49 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 54 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 80 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1255 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4278 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 66 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 592 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 10 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 552 | 0.100 |
Why?
| | Walking | 1 | 2017 | 545 | 0.090 |
Why?
| | Dabigatran | 1 | 2012 | 29 | 0.090 |
Why?
| | Canada | 2 | 2025 | 428 | 0.090 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.090 |
Why?
| | Chlorides | 1 | 2013 | 141 | 0.090 |
Why?
| | Sleep Stages | 1 | 2012 | 75 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 633 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 211 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1182 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 88 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 99 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 28 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 155 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 75 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 101 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 57 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 977 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 390 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 250 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 201 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 91 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 222 | 0.080 |
Why?
| | Levamisole | 1 | 2011 | 21 | 0.080 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.080 |
Why?
| | Laparoscopy | 1 | 2016 | 475 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5389 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 567 | 0.080 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.080 |
Why?
| | Molecular Structure | 1 | 2012 | 498 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 575 | 0.080 |
Why?
| | Sports | 1 | 2013 | 211 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 172 | 0.080 |
Why?
| | Universities | 1 | 2013 | 451 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 13 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 15 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 48 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 31 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 280 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 142 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 976 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 245 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 88 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 26 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.070 |
Why?
| | Risperidone | 1 | 2009 | 29 | 0.070 |
Why?
| | Potassium | 1 | 2009 | 152 | 0.070 |
Why?
| | Role | 1 | 2009 | 29 | 0.070 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 139 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 24 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 163 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 437 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 105 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 63 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 37 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 375 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 462 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 192 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 228 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 284 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 335 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 49 | 0.070 |
Why?
| | Workload | 1 | 2010 | 170 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 81 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 18 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 23 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 530 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 198 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 464 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 80 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 58 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 90 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 357 | 0.060 |
Why?
| | Students | 1 | 2013 | 661 | 0.060 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.060 |
Why?
| | Laboratories | 1 | 2008 | 109 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1091 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 327 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 105 | 0.060 |
Why?
| | Polypharmacy | 1 | 2008 | 92 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 179 | 0.060 |
Why?
| | Formates | 1 | 2006 | 16 | 0.060 |
Why?
| | Research | 2 | 2011 | 428 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 201 | 0.060 |
Why?
| | Military Personnel | 1 | 2014 | 709 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 23 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1264 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 203 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 46 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 427 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 704 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 52 | 0.060 |
Why?
| | Probability | 2 | 2010 | 308 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 70 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 50 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 326 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 155 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 21 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 158 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2424 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 176 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 84 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1964 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 96 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1559 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 940 | 0.050 |
Why?
| | Risk | 1 | 2007 | 909 | 0.050 |
Why?
| | Spine | 1 | 2006 | 182 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 707 | 0.050 |
Why?
| | Water | 1 | 2008 | 469 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 311 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 605 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2312 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 267 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 302 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 398 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 120 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 329 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 880 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Urea | 1 | 2023 | 84 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 488 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 429 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 399 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 83 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7180 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 380 | 0.050 |
Why?
| | Internet | 1 | 2007 | 698 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 67 | 0.040 |
Why?
| | Urban Population | 2 | 2019 | 490 | 0.040 |
Why?
| | Prevalence | 3 | 2015 | 2815 | 0.040 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 12 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 92 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 51 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 545 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2447 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 41 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 54 | 0.040 |
Why?
| | Certification | 1 | 2020 | 119 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 55 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 15 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 678 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 83 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 115 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 846 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1304 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 37 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 35 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 597 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 136 | 0.030 |
Why?
| | North America | 1 | 1999 | 310 | 0.030 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 46 | 0.030 |
Why?
| | Laparotomy | 1 | 1998 | 112 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1367 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 181 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 337 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 512 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 700 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 893 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 600 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 281 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1312 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 280 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2382 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1084 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 108 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 27 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 53 | 0.030 |
Why?
| | Observation | 1 | 2014 | 54 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 108 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 143 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 380 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 946 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 100 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 99 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 100 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2013 | 36 | 0.020 |
Why?
| | Protein Binding | 1 | 2020 | 2270 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 259 | 0.020 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 80 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 69 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 158 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 383 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 69 | 0.020 |
Why?
| | Iron | 1 | 1994 | 359 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 68 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 60 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 24 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 162 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1025 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1232 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 131 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 147 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 582 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 109 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 688 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 422 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 238 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 200 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 130 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 777 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 397 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 612 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 358 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 597 | 0.020 |
Why?
| | Safety | 1 | 2010 | 355 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 998 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 456 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 625 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 556 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 643 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 97 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1833 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 91 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1241 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 68 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 44 | 0.010 |
Why?
| | Metabolomics | 1 | 2012 | 726 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2006 | 136 | 0.010 |
Why?
| | European Union | 1 | 2005 | 12 | 0.010 |
Why?
| | Electric Countershock | 1 | 2006 | 126 | 0.010 |
Why?
| | Fever | 1 | 2007 | 311 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 100 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 175 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 574 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6424 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 203 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 169 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 851 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 168 | 0.010 |
Why?
| | Swine | 1 | 2006 | 831 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 113 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 506 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3157 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 70 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1047 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 195 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1759 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1119 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1812 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1834 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2525 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5592 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2870 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|